Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to -$344000.0.

  • Tango Therapeutics' Change in Account Payables fell 11128.98% to -$344000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year decrease of 27012.15%. This contributed to the annual value of -$1.2 million for FY2024, which is 3055.72% up from last year.
  • Per Tango Therapeutics' latest filing, its Change in Account Payables stood at -$344000.0 for Q3 2025, which was down 11128.98% from -$880000.0 recorded in Q2 2025.
  • Tango Therapeutics' 5-year Change in Account Payables high stood at $4.5 million for Q3 2022, and its period low was -$2.8 million during Q2 2024.
  • In the last 5 years, Tango Therapeutics' Change in Account Payables had a median value of -$344000.0 in 2025 and averaged -$8105.3.
  • Within the past 5 years, the most significant YoY rise in Tango Therapeutics' Change in Account Payables was 4353636.36% (2021), while the steepest drop was 3653756.05% (2021).
  • Over the past 5 years, Tango Therapeutics' Change in Account Payables (Quarter) stood at $365000.0 in 2021, then plummeted by 384.93% to -$1.0 million in 2022, then soared by 91.54% to -$88000.0 in 2023, then crashed by 2748.86% to -$2.5 million in 2024, then surged by 86.28% to -$344000.0 in 2025.
  • Its Change in Account Payables was -$344000.0 in Q3 2025, compared to -$880000.0 in Q2 2025 and $1.6 million in Q1 2025.